DDInter779 DDInter1376
An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Foscarnet {u} (Compound) binds {v} (Gene) SLC22A6
Foscarnet {u} (Compound) is included by {v} (Pharmacologic Class) DNA Polymerase Inhibitors
Foscarnet {u} (Compound) causes {v} (Side Effect) Blood urea increased
Foscarnet {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Foscarnet {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palonosetron
Foscarnet {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Foscarnet {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Foscarnet {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Foscarnet (Compound) binds SLC22A6 (Gene)
Foscarnet (Compound) is included by DNA Polymerase Inhibitors (Pharmacologic Class)
Foscarnet (Compound) causes Blood urea increased (Side Effect)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Prednisone
Foscarnet may lead to a major life threatening interaction when taken with Iohexol
Foscarnet may lead to a major life threatening interaction when taken with Anagrelide